Compare Logitech International SA (LOGI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs State Street SPDR S&P Biotech ETF — how do they compare? Logitech International SA trades at $103.6 (market cap $14.65B), while State Street SPDR S&P Biotech ETF trades at $151.8. The key difference: Logitech International SA pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Logitech International SA nearer its low. Which is the better fit depends on your goals.
| LOGI | XBI | |
|---|---|---|
Market Cap | $14.65B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $126.69 | $164.28 |
52-Week Low | $85.84 | $85.16 |
Enterprise Value | $13.00B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.83, down 0.98% on the day, with a bullish technical outlook supported by moving averages and strong fundamentals including a 14.69% net margin and consistent earnings beats. Recent product launches like the G3 Series and Spotlight 2 presenter highlight innovation, while a partnership with Call of Duty: Modern Warfare 4 boosts gaming segment prospects. Cash flow trends show operational strength with 2025 operating cash flow at $842.56M.
The stock offers upside to the $113 consensus price target, driven by B2B and AI product expansion, but faces risks from competitive pressures and reliance on consumer spending. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid valuation metrics like a P/E of 21.43.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
